期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 67, 期 3, 页码 341-351出版社
SPRINGER
DOI: 10.1007/s00262-017-2099-3
关键词
Merkel cell carcinoma; Epidemiology; Cell of origin; Merkel cell polyomavirus; Immunotherapy; IMMOMEC
资金
- European Commission [277,775/IMMOMEC]
- BMBF [03VP01062/CTCelect]
- Hiege Stiftung
- German Cancer Consortium (DKTK)
- German Federal Ministry of Education and Science (BMBF) [01ER1305]
- US Public Health Service [R01CA63113, R01CA173023, P01CA050661, K24-CA139052, RO1-CA176841]
- DFCI Helen Pappas Merkel Cell Research Fund
- Claudia Adams Barr Program in Cancer Research
- UW MCC Gift Fund
Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据